Despite considerable evidence supporting the existence of host immunity to tumors, attempts to elicit anti-tumor immune responses in human shave had only limited success. A critical challenge in tumor immunology is antigen delivery. Dendritic cells (DC's) are potent antigen presenting cells, capable of initiating antigen-specific T cell-dependent immune responses. The goal of this proposal is to elucidate key factors determining the in vivo immunogenicity of DC-based immunizations and to manipulate these factors to develop innovative strategies for using DC's to induce T-cell mediated tumor immunity. To accomplish this we will pursue 2 specific aims.
In SPECIFIC AIM 1, we will perform experiments to determine the molecular basis for ex vivo antigen-loading of dendritic cells. They hypothesis underlying this aim is that the capacity of DC's to generate and/or present peptide epitopes from various forms of administered antigen will be a critical factor in determining immunogenicity. Our goal is to determine parameters of DC antigen loading which will result in optimal T-cell mediated tumor immunity. To achieve this goal we will study the capacity of DC's to generate and present relevant peptide epitopes from various forms of administered antigen. Studies in SPECIFIC AIM 2 are designed to define and manipulate factors critical to in vivo immunogenicity of antigen-loaded DC's. They hypothesis underlying this aim is that factors in addition to antigen loading will affect antigen presentation, DC trafficking and localization, and ultimately the immunogenicity of antigen-loading DC's in the host. The goal is to elucidate key factors influencing the in vivo immunogenicity of antigen-loaded dendritic cells and to manipulate these factors to induce tumor immunity in vivo. Parameters which will be investigated include: method of antigen load, lineage and """"""""maturity"""""""" of DC's, and the dose, sequence and route of administration. Insights gained from these studies should be directly applicable to the design of innovative strategies for DC-based anti-tumor immunization.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA073743-04
Application #
6414821
Study Section
Project Start
2001-01-01
Project End
2001-12-31
Budget Start
Budget End
Support Year
4
Fiscal Year
2001
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Macatangay, Bernard J C; Riddler, Sharon A; Wheeler, Nicole D et al. (2016) Therapeutic Vaccination With Dendritic Cells Loaded With Autologous HIV Type 1-Infected Apoptotic Cells. J Infect Dis 213:1400-9
Lohmueller, Jason J; Sato, Shuji; Popova, Lana et al. (2016) Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential. Sci Rep 6:31740
Zhang, Lixin; Vlad, Anda; Milcarek, Christine et al. (2013) Human mucin MUC1 RNA undergoes different types of alternative splicing resulting in multiple isoforms. Cancer Immunol Immunother 62:423-35
Sun, Chengqun; Heid, Michelle E; Keyel, Peter A et al. (2013) The second transmembrane domain of P2X7 contributes to dilated pore formation. PLoS One 8:e61886
Kimura, Takashi; McKolanis, John R; Dzubinski, Lynda A et al. (2013) MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. Cancer Prev Res (Phila) 6:18-26
Miskov-Zivanov, Natasa; Turner, Michael S; Kane, Lawrence P et al. (2013) The duration of T cell stimulation is a critical determinant of cell fate and plasticity. Sci Signal 6:ra97
Keyel, Peter A; Roth, Robyn; Yokoyama, Wayne M et al. (2013) Reduction of streptolysin O (SLO) pore-forming activity enhances inflammasome activation. Toxins (Basel) 5:1105-18
Keyel, Peter A; Tkacheva, Olga A; Larregina, Adriana T et al. (2012) Coordinate stimulation of macrophages by microparticles and TLR ligands induces foam cell formation. J Immunol 189:4621-9
Cramer, Daniel W; Finn, Olivera J (2011) Epidemiologic perspective on immune-surveillance in cancer. Curr Opin Immunol 23:265-71
Morel, Penelope A; Turner, Michael S (2011) Dendritic cells and the maintenance of self-tolerance. Immunol Res 50:124-9

Showing the most recent 10 out of 90 publications